Bonothyrk

Bonothyrk is a peptide bioregulator derived from the parathyroid gland. It helps regulate calcium and phosphate balance, supports bone strength, and aids in hormone signaling that contributes to skeletal and neuromuscular stability. It may be useful in managing age-related mineral imbalance, parathyroid dysfunction, and bone demineralization. Bonothyrk contains peptide fractions derived from the parathyroid glands of healthy young animals. These short peptides are homologous to those found in the human parathyroid gland, which plays a central role in the endocrine regulation of calcium and phosphorus metabolism. The parathyroid gland releases parathyroid hormone (PTH), which regulates serum calcium levels via actions on bone, kidneys, and the gastrointestinal tract. Bonothyrk's peptide complex supports the homeostatic balance of this system by restoring normal peptide-protein signaling within parathyroid tissue, which may decline due to age or disease. Bonothyrk is often used in preventive or supportive protocols for conditions such as osteoporosis, muscle cramps, chronic hypocalcemia, or disturbances following thyroid or parathyroid surgery.

- Managing a parathyroid-related condition such as hyperparathyroidism or hypoparathyroidism

- Issues related to calcium imbalance (bone density loss or muscle cramps)

- Support bone metabolism and mineral homeostasis

- Optimize hormonal signaling associated with aging and skeletal health

Mechanism of Action

How this peptide works in the body

Peptide Receptor Binding and Parathyroid Stimulation

Bonothyrk's peptides selectively bind to regulatory regions in parathyroid cells, promoting transcription and translation of endogenous proteins involved in calcium-sensing and PTH secretion. This leads to restored or enhanced synthesis of native parathyroid hormone (PTH), which regulates mineral balance.

**Regulation of Calcium and Phosphate Homeostasis **Restored PTH signaling modulates:

Bone Resorption: PTH stimulates osteoblast-mediated activation of osteoclasts to release calcium from bone into the bloodstream when levels are low. Bonothyrk helps restore this feedback loop.

Renal Reabsorption: PTH reduces renal excretion of calcium by increasing reabsorption in the distal tubules of the nephron, while promoting phosphate excretion.

Vitamin D Activation: It enhances conversion of 25(OH)D to active 1,25(OH)₂D₃ (calcitriol) in the kidneys, increasing calcium absorption from the gastrointestinal tract.

Cellular Regeneration of Parathyroid Tissue

Peptides in Bonothyrk support ribosomal function and cellular protein synthesis within parathyroid tissue, helping repair age-related cellular decline. Enhanced protein synthesis supports stable endocrine output and tissue resilience.

Hormonal Feedback Stabilization

Improved regulation of PTH levels leads to balanced feedback interaction with calcitonin (from the thyroid) and vitamin D metabolism, stabilizing calcium dynamics without excessive bone turnover or hypocalcemia.